Original Research| Volume 51, ISSUE 8, P915-921, May 2015

Population based study on sentinel node biopsy before or after neoadjuvant chemotherapy in clinically node negative breast cancer patients: Identification rate and influence on axillary treatment

Published:April 06, 2015DOI:


      The timing of the sentinel lymph node biopsy (SNB) is controversial in clinically node negative patients receiving neoadjuvant chemotherapy (NAC). We studied variation in the timing of axillary staging in breast cancer patients who received NAC and the subsequent axillary treatment in The Netherlands.
      Patients diagnosed with clinically node negative primary breast cancer between 1st January 2010 and 30th June 2013 who received NAC and SNB were selected from the Netherlands Cancer Registry. Data on patient and tumour characteristics, axillary staging and treatment were analysed. Two groups were defined: (1) patients with SNB before NAC (N = 980) and (2) patients with SNB after NAC (N = 203).
      Eighty-three percent of patients underwent SNB before NAC, with large regional variation (35–99%). The SN identification rate differed for SNBs conducted before and after NAC (98% versus 95%; p = 0.032). A lower proportion of patients had a negative SNB when assessed before NAC compared to after (54% versus 67%; p = 0.001). The proportion of patients receiving any axillary treatment was higher for those with SNB before NAC than after (45% versus 33%; p = 0.006).
      In conclusion, variation exists in the timing of SNB in clinical practice in The Netherlands for clinically node negative breast cancer patients receiving NAC. The post-NAC SN procedure is, despite some lower SN identification rate, associated with a significantly less frequent axillary treatment and thus with less expected morbidity. The effect on recurrence rate is not yet clear. Patients in this registry will be followed prospectively for long-term outcome.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Krag D.N.
        • Anderson S.J.
        • Julian T.B.
        • Brown A.M.
        • Harlow S.P.
        • Ashikaga T.
        • et al.
        Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial.
        Lancet Oncol. 2007; 8: 881-888
        • Krag D.N.
        • Anderson S.J.
        • Julian T.B.
        • Brown A.M.
        • Harlow S.P.
        • Costantino J.P.
        • et al.
        Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial.
        Lancet Oncol. 2010; 11: 927-933
        • Veronesi U.
        • Viale G.
        • Paganelli G.
        • Zurrida S.
        • Luini A.
        • Galimberti V.
        • et al.
        Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study.
        Ann Surg. 2010; 251: 595-600
        • Roumen R.M.
        • Pijpers H.J.
        • Thunnissen F.B.
        • Ruers T.J.
        Summary of the guideline ’Sentinel node biopsy in breast cancer’. Dutch Work Group ‘Sentinel Node Biopsy for Breast Cancer’’.
        Ned Tijdschr Geneeskd. 2000; 144: 1864-1867
        • Ho V.K.
        • van der Heiden-van der Loo M.
        • Rutgers E.J.
        • van Diest P.J.
        • Hobbelink M.G.
        • Tjan-Heijnen V.C.
        • et al.
        Implementation of sentinel node biopsy in breast cancer patients in the Netherlands.
        Eur J Cancer (Oxford, England: 1990). 2008; 44: 683-691
        • Chung A.
        • Giuliano A.
        Axillary staging in the neoadjuvant setting.
        Ann Surg Oncol. 2010; 17: 2401-2410
        • Lyman G.H.
        • Temin S.
        • Edge S.B.
        • Newman L.A.
        • Turner R.R.
        • Weaver D.L.
        • et al.
        Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update.
        J Clin Oncol. 2014; 32: 1365-1383
        • Alvarado R.
        • Yi M.
        • Le-Petross H.
        • Gilcrease M.
        • Mittendorf E.A.
        • Bedrosian I.
        • et al.
        The role for sentinel lymph node dissection after neoadjuvant chemotherapy in patients who present with node-positive breast cancer.
        Ann Surg Oncol. 2012; 19: 3177-3184
        • Boileau J.F.
        • Poirier B.
        • Basik M.
        • Holloway C.M.
        • Gaboury L.
        • Sideris L.
        • et al.
        Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study.
        J Clin Oncol. 2014;
        • Boughey J.C.
        • Suman V.J.
        • Mittendorf E.A.
        • Ahrendt G.M.
        • Wilke L.G.
        • Taback B.
        • et al.
        Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial.
        JAMA. 2013; 310: 1455-1461
        • Kuehn T.
        • Bauerfeind I.
        • Fehm T.
        • Fleige B.
        • Hausschild M.
        • Helms G.
        • et al.
        Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study.
        Lancet Oncol. 2013; 14: 609-618
        • Rouzier R.
        • Extra J.M.
        • Klijanienko J.
        • Falcou M.C.
        • Asselain B.
        • Vincent-Salomon A.
        • et al.
        Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes.
        J Clin Oncol. 2002; 20: 1304-1310
        • Hunt K.K.
        • Yi M.
        • Mittendorf E.A.
        • Guerrero C.
        • Babiera G.V.
        • Bedrosian I.
        • et al.
        Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients.
        Ann Surg. 2009; 250: 558-566
        • Classe J.M.
        • Bordes V.
        • Campion L.
        • Mignotte H.
        • Dravet F.
        • Leveque J.
        • et al.
        Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French prospective multicentric study.
        J Clin Oncol. 2009; 27: 726-732
        • Tausch C.
        • Konstantiniuk P.
        • Kugler F.
        • Reitsamer R.
        • Roka S.
        • Postlberger S.
        • et al.
        Sentinel lymph node biopsy after preoperative chemotherapy for breast cancer: findings from the Austrian Sentinel Node Study Group.
        Ann Surg Oncol. 2008; 15: 3378-3383
        • Tafra L.
        • Lannin D.R.
        • Swanson M.S.
        • Van Eyk J.J.
        • Verbanac K.M.
        • Chua A.N.
        • et al.
        Multicenter trial of sentinel node biopsy for breast cancer using both technetium sulfur colloid and isosulfan blue dye.
        Ann Surg. 2001; 233: 51-59
        • Kuerer H.M.
        • Sahin A.A.
        • Hunt K.K.
        • Newman L.A.
        • Breslin T.M.
        • Ames F.C.
        • et al.
        Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy.
        Ann Surg. 1999; 230: 72-78
        • Fontein D.B.
        • van de Water W.
        • Mieog J.S.
        • Liefers G.J.
        • van de Velde C.J.
        Timing of the sentinel lymph node biopsy in breast cancer patients receiving neoadjuvant therapy - recommendations for clinical guidance.
        Eur J Surg Oncol. 2013; 39: 417-424
        • Goldhirsch A.
        • Ingle J.N.
        • Gelber R.D.
        • Coates A.S.
        • Thurlimann B.
        • Senn H.J.
        Thresholds for therapies: highlights of the St. Gallen International Expert Consensus on the primary therapy of early breast cancer 2009.
        Ann Oncol. 2009; 20: 1319-1329
      1. Sobin LH, Gospodarowicz MK, Wittekind C. TNM Classification of malignant tumours. International Union against cancer (UICC). Chichester: Wiley-Blackwell; 2010.

        • van Deurzen C.H.
        • Vriens B.E.
        • Tjan-Heijnen V.C.
        • van der Wall E.
        • Albregts M.
        • van Hilligersberg R.
        • et al.
        Accuracy of sentinel node biopsy after neoadjuvant chemotherapy in breast cancer patients: a systematic review.
        Eur J Cancer (Oxford, England: 1990). 2009; 45: 3124-3130
        • Xing Y.
        • Foy M.
        • Cox D.D.
        • Kuerer H.M.
        • Hunt K.K.
        • Cormier J.N.
        Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer.
        Br J Surg. 2006; 93: 539-546
        • Mamounas E.P.
        • Brown A.
        • Anderson S.
        • Smith R.
        • Julian T.
        • Miller B.
        • et al.
        Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.
        J Clin Oncol. 2005; 23: 2694-2702
      2. van der Heiden-van der Loo M. Defining the quality of surgical breast cancer care. Utrecht: Utrecht University; 2013.

        • Giuliano A.E.
        • McCall L.
        • Beitsch P.
        • Whitworth P.W.
        • Blumencranz P.
        • Leitch A.M.
        • et al.
        Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial.
        Ann Surg. 2010; 252 ([discussion 32–3]): 426-432
        • McGale P.
        • Taylor C.
        • Correa C.
        • Cutter D.
        • Duane F.
        • Ewertz M.
        • et al.
        Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials.
        Lancet. 2014; 383: 2127-2135
        • Darby S.
        • McGale P.
        • McGale C.
        • Taylor C.
        • Arriagada R.
        • et al.
        • Early Breast Cancer Trialists’ Collaborative G
        Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials.
        Lancet. 2011; 378: 1707-1716